Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC. Denduluri N, et al. Among authors: eisen a. J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18. J Clin Oncol. 2016. PMID: 27091714
Anthracycline adjuvant chemotherapy: how much is enough?
Levine M, Eisen A. Levine M, et al. Among authors: eisen a. J Clin Oncol. 2001 Feb 1;19(3):599-601. doi: 10.1200/JCO.2001.19.3.599. J Clin Oncol. 2001. PMID: 11157008 No abstract available.
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. Chlebowski RT, et al. Among authors: eisen a. J Clin Oncol. 2002 Aug 1;20(15):3328-43. doi: 10.1200/JCO.2002.06.029. J Clin Oncol. 2002. PMID: 12149307 Review.
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Metcalfe K, et al. Among authors: eisen a. J Clin Oncol. 2004 Jun 15;22(12):2328-35. doi: 10.1200/JCO.2004.04.033. J Clin Oncol. 2004. PMID: 15197194
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Eisen A, et al. J Clin Oncol. 2005 Oct 20;23(30):7491-6. doi: 10.1200/JCO.2004.00.7138. J Clin Oncol. 2005. PMID: 16234515
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Chen S, et al. Among authors: eisen a. J Clin Oncol. 2006 Feb 20;24(6):863-71. doi: 10.1200/JCO.2005.03.6772. J Clin Oncol. 2006. PMID: 16484695 Free PMC article.
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Ellard SL, et al. Among authors: eisen a. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687332 Clinical Trial.
Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L. Chiarelli AM, et al. Among authors: eisen a. J Clin Oncol. 2014 Jul 20;32(21):2224-30. doi: 10.1200/JCO.2013.52.8331. Epub 2014 Jun 16. J Clin Oncol. 2014. PMID: 24934793
812 results